

A1
Cmld.

which claims the priority of U.S. Provisional Application No. 60/028,269 filed October 11, 1996, now abandoned, which are all incorporated herein by reference.

In the Claims: Cancel claims 1-20 and 33-~~58~~⁵⁶ and add new claims ~~59~~⁵⁷-83 as follows:

R1.126 ~~59.~~^{57.} (New) The conjugates of claim 21, wherein the targeting ligand is selected from the group consisting of water soluble vitamins, apolipoproteins, insulin, galactose, Mac-1, PECAM-1/CD31, fibronectin, osteopontin, RGD sequences of matrix proteins, HIV GP 120/41 domain peptomers, GP120 C4 domain peptomers, T cell tropic isolates, SDF-1 chemokines, Macrophage tropic isolates, anti-cell surface receptor antibodies or fragments thereof, pyridoxyl ligands, biotin, RGD peptide mimetics, YIGSRG protein, $\alpha_v\beta_5$, IL-8, anti-E-selectin Fab.

~~58.~~^{58.} (New) The conjugates of claim 59, wherein the anti-cell surface receptor antibodies or fragments thereof is selected from the group consisting of anti-HER2/neu, anti-selectin and anti-VEGF pyridoxyl.

~~61.~~^{59.} (New) The conjugates of claim 59, wherein the pyridoxyl ligand is selected from the group consisting of pyridoxal, pyridoxine, pyridoxamine, pyridoxal 5'-phosphate and N-(4'-pyridoxyl)amines.

~~62.~~^{60.} (New) A targeting conjugate, comprising (i) a lipid having a polar head group and a hydrophobic tail, (ii) a hydrophilic polymer having a proximal end and a distal end, said polymer attached at its proximal end to the head group of the

lipid, and (iii) a targeting ligand attached to the distal end of the polymer.

Pl. 126

~~61.~~
64. (New) The conjugate of claim 62, wherein the targeting ligand is an antibody or an antibody fragment.

~~62.~~
64. (New) The conjugate of claim 63, wherein the antibody or antibody fragment is a humanized murine antibody.

~~63.~~
65. (New) The conjugate of claim 62, wherein the targeting ligand specifically binds to an extracellular domain of a growth factor receptor.

~~64.~~
66. (New) The conjugate of claim 65, wherein the receptors are selected from the group consisting of c-erbB-2 protein product of the HER2/neu oncogene, epidermal growth factor receptor, basic fibroblast growth factor receptor and vascular endothelial growth factor receptor.

~~65.~~
67. (New) The conjugate of claim 62, wherein the targeting ligand binds a receptor selected from the group consisting of E-selectin receptor, L-selectin receptor, P-selectin receptor, folate receptor, CD4 receptor, CD19 receptor, $\alpha\beta$ integrin receptors and chemokine receptors.

~~66.~~
68. (New) The conjugate of claim 62, wherein the targeting ligand binds a receptor on a malignant B-cell or T-cell, said receptor selected from the group consisting of CD19, CD20, CD22, CD4, CD7 and CD8.

~~67.~~
69. (New) The conjugate of claim 62, wherein the targeting ligand is selected from the group consisting of folic acid,

pyridoxal phosphate, vitamin B12, sialyl Lewis^x, transferrin, epidermal growth factor, basic fibroblast growth factor, vascular endothelial growth factor, VCAM-1, ICAM-1, PECAM-1, RGD peptides and NGR peptides.

21.126

~~68~~
70.

(New) The conjugate of claim 62, wherein the targeting ligand is selected from the group consisting of water soluble vitamins, apolipoproteins, insulin, galactose, Mac-1, PECAM-1/CD31, fibronectin, osteopontin, RGD sequences of matrix proteins, HIV GP 120/41 domain peptomers, GP120 C4 domain peptomers, T cell tropic isolates, SDF-1 chemokines, Macrophage tropic isolates, anti-cell surface receptor antibodies or fragments thereof, pyridoxyl ligands, biotin, RGD peptide mimetics, YIGSRG protein, $\alpha_v\beta_5$, IL-8, anti-E-selectin Fab.

AI
Cmt

Sub
Pl

~~69~~
71.

(New) The conjugate of claim 70, wherein the anti-cell surface receptor antibodies or fragments thereof is selected from the group consisting of anti-HER2/neu, anti-selectin and anti-VEGF pyridoxyl.

~~70~~
72.

(New) The conjugate of claim 70, wherein the pyridoxyl ligand is selected from the group consisting of pyridoxal, pyridoxine, pyridoxamine, pyridoxal 5'-phosphate and N-(4'-pyridoxyl)amines.

~~71~~
73.

(New) A liposome composition comprising targeting conjugate comprised of (i) a lipid having a polar head group and a hydrophobic tail, (ii) a hydrophilic polymer having a proximal end and a distal end, said polymer attached at its proximal end to the head group of the lipid, and (iii) a targeting ligand attached to the distal end of the polymer.

R1.126

~~72.~~
74. (New) The composition of claim 73, wherein the targeting ligand is an antibody or an antibody fragment.

~~73.~~
75. (New) The composition of claim 74, wherein the antibody or antibody fragment is a humanized murine antibody.

~~74.~~
76. (New) The composition of claim 73, wherein the targeting ligand specifically binds to an extracellular domain of a growth factor receptor.

~~75.~~
77. (New) The composition of claim 76, wherein the receptors are selected from the group consisting of c-erbB-2 protein product of the HER2/neu oncogene, epidermal growth factor receptor, basic fibroblast growth factor receptor and vascular endothelial growth factor receptor.

~~76.~~
78. (New) The composition of claim 73, wherein the targeting ligand binds a receptor selected from the group consisting of E-selectin receptor, L-selectin receptor, P-selectin receptor, folate receptor, CD4 receptor, CD19 receptor, $\alpha\beta$ integrin receptors and chemokine receptors.

~~77.~~
79. (New) The composition of claim 73, wherein the targeting ligand binds a receptor on a malignant B-cell or T-cell, said receptor selected from the group consisting of CD19, CD20, CD22, CD4, CD7 and CD8.

~~78.~~
80. (New) The composition of claim 73, wherein the targeting ligand is selected from the group consisting of folic acid, pyridoxal phosphate, vitamin B12, sialyl Lewis^x, transferrin, epidermal growth factor, basic fibroblast growth factor, vascular

A2
Cm
406,670,680,690,700,710,720,730,740,750,760,770,780,790,800,810,820,830,840,850,860,870,880,890,900,910,920,930,940,950,960,970,980,990,1000

endothelial growth factor, VCAM-1, ICAM-1, PECAM-1, RGD peptides and NGR peptides.

R1.126
~~79.~~ 81. (New) The composition of claim 73, wherein the targeting ligand is selected from the group consisting of water soluble vitamins, apolipoproteins, insulin, galactose, Mac-1, PECAM-1/CD31, fibronectin, osteopontin, RGD sequences of matrix proteins, HIV GP 120/41 domain peptomers, GP120 C4 domain peptomers, T cell tropic isolates, SDF-1 chemokines, Macrophage tropic isolates, anti-cell surface receptor antibodies or fragments thereof, pyridoxyl ligands, biotin, RGD peptide mimetics, YIGSRG protein, $\alpha_v\beta_5$, IL-8, anti-E-selectin Fab.

A2
cancel.
~~80.~~ 82. (New) The composition of claim 81, wherein the anti-cell surface receptor antibodies or fragments thereof is selected from the group consisting of anti-HER2/neu, anti-selectin and anti-VEGF pyridoxyl.

81.
~~83.~~ 83. (New) The composition of claim 81, wherein the pyridoxyl ligand is selected from the group consisting of pyridoxal, pyridoxine, pyridoxamine, pyridoxal 5'-phosphate and N-(4'-pyridoxyl)amines.--